<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The neuroprotective effects of YM872 ([2,3-dioxo-7-(<z:chebi fb="0" ids="50053">1H-imidazol-1-yl</z:chebi>)6-<z:chebi fb="13" ids="29785">nitro</z:chebi>-1,2,3,4-tetrahydro-1-quinoxal inyl]<z:chebi fb="22" ids="15366">acetic acid</z:chebi> monohydrate), a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-<z:chebi fb="0" ids="17272">propionate</z:chebi> (AMPA) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> with high water solubility, were examined in rats with transient middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion </plain></SENT>
<SENT sid="1" pm="."><plain>The right <z:chebi fb="70" ids="34342">MCA</z:chebi> of male SD rats was occluded for 3 h using the intraluminal suture occlusion method </plain></SENT>
<SENT sid="2" pm="."><plain>YM872 significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume 24 hours after occlusion, at dosages of 20 and 40 mg/kg/h (iv infusion) when given for 4 h immediately after occlusion </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, delayed administration of YM872 (20 mg/kg/h iv infusion for 4 h, starting 2 or 3 h after the occlusion) also reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and the neurological deficits measured at 24 h </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, the therapeutic efficacy of YM872 persisted for at least seven days after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion in animals treated with YM872 for 4 h starting 2 h after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion </plain></SENT>
<SENT sid="5" pm="."><plain>These data demonstrate that AMPA receptors contribute to the development of neuronal damage after reperfusion as well as during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in the focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> models and that the <z:hpo ids='HP_0011009'>acute</z:hpo> effect of the blockade of AMPA receptors persists over a long time period </plain></SENT>
<SENT sid="6" pm="."><plain>YM872 shows promise as an effective treatment for patients suffering from <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>